In this study, the encapsulated Fe₃O₄@rifampin (RIF)/buprenorphine (BUP)/carboxy methyl modified with modified fatty acids (CMCs-MFAs) nanoparticles were hybridized to form Fe₃O₄@RIF-BUP-CMCs-MNFAs NPs. The best fatty acid that could be modified in this process was oleic acid. This paper examines the changes (pH, absorption rate, drug release, in vivo test (30 male) in selected Wistar rats. All males were orally addicted to morphine after 21 days. After establishing dependence based on an observation of behavioral parameters the ability to quit the new drug was evaluated. In vitro and in vitro tests on antibacterial activity and multiple intestinal inflammation in addicts were conducted. The slow release study revealed that CMCs-MFAs NPs increase the release and longer release of RIF in the body. It did not increase significantly the measurement of enzymes (ALT and AST). The production of NPs caused less damage to liver tissue than BUP while trying to quit addiction. Images of the liver revealed that the designed NPs did less damage to liver tissue than the main drug BUP. Antibacterial activity showed more inflammation for BUP without NPs and less inflammation with the Fe₃O₄@RIF-BUP-CMCs-MFAs NPs. In this project the modified dose was reduced from 0.004 to 0.0005 µg. The next goal is to extend the release of BUP in the body using CMCs-MFAs (72–96 h).

在这项研究中，囊化的Fe ₃ O ₄利福平（RIF）/丁丙诺啡（BUP）/用改性脂肪酸（CMCs-MFAs）纳米粒子改性的羧甲基被杂交形成Fe ₃ O ₄@ RIF-BUP-CMCs-MNFAs NP。在此过程中可以改性的最佳脂肪酸是油酸。本文研究了选定的Wistar大鼠的变化（pH，吸收率，药物释放，体内试验（30只雄性）。所有雄性在21天后都口服吗啡成瘾。对该新药戒烟进行了评估，对成瘾者进行了抗菌活性和多发性肠道炎症的体外和体外试验，缓慢释放研究表明，CMCs-MFAs NPs可以增加体内RIF的释放和延长释放。在试图戒除成瘾时，NPs的产生对肝脏组织的损害要比BUP少，从而大大减少了酶（ALT和AST）的含量。肝脏图像显示，与主要药物BUP相比，设计的NP对肝脏组织的损害较小。抗菌活性显示，没有NP的BUP的炎症更多，而Fe的炎症更少₃ O ₄ @ RIF-BUP-CMCs-MFA NP。在该项目中，修改剂量从0.004降低到0.0005 µg。下一个目标是使用CMCs-MFA（72-96小时）延长BUP在体内的释放。